Boston Scientific Corp (BSX)
Boston Scientific Corp (BSX) carries a ŷRobot AI score of 46 out of 100. The model's fair value estimate is $40.23, 9.3% below the last close of $44.35. The chart signal reads Hold.
| Metric | BSX |
|---|---|
| AI score | 46 / 100 |
| Chart signal | Hold |
| Fair value estimate | $40.23 |
| Upside to fair value | -9.3% |
| Previous close | $44.35 |
| P/E | 17.90 |
| Price / sales | 2.95 |
| Market cap | $64.07B |
| EPS | 2.37 |
| Revenue growth | 15.5% |
| 1-year price change | 1.8% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, Merck & Company Inc, UnitedHealth Group Incorporated, Novartis AG ADR.
Questions about BSX
Is BSX overvalued or undervalued right now?
As of Oct 29, 2026, ŷRobot's fair-value model estimates Boston Scientific Corp (BSX) at $40.23 against a last close of $44.35, implying 9.3% downside to the model's estimate.
Is BSX's chart signal bullish or bearish?
The chart-signal model classifies BSX as Neutral as of Nov 13, 2026, with a signal score of 0.03 on a -1 to 1 scale.
What is BSX's ŷRobot AI score?
BSX scores 46 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Nov 13, 2026.
Is BSX stock expensive on P/E and P/S?
BSX trades at 17.9 times earnings and 2.9 times sales as of Nov 13, 2026.
What does BSX's seasonal forecast show?
ŷRobot's seasonal forecast curve for BSX reads -1.7% at 30 days, +3.7% at 90 days, and +1.8% at one year as of Nov 13, 2026. Seasonal tendencies are historical patterns, not predictions.
How fast is BSX growing?
Boston Scientific Corp's revenue growth is +15.5% and free-cash-flow growth is -1.9% on the latest reported figures.
BSX chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.